| Authors: |
Ellingsen EB; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway espen.ellingsen@ultimovacs.com.; Faculty of Medicine, University of Oslo, Oslo, Norway.; Ultimovacs ASA, Oslo, Norway., Aamdal E; Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Department of Oncology, Akershus University Hospital, Lørenskog, Norway., Guren T; Department of Oncology, Oslo University Hospital, Oslo, Norway., Lilleby W; Department of Oncology, Oslo University Hospital, Oslo, Norway., Brunsvig PF; Department of Oncology, Oslo University Hospital, Oslo, Norway., Mangsbo SM; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.; Ultimovacs AB, Uppsala, Sweden., Aamdal S; Ultimovacs ASA, Oslo, Norway., Hovig E; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Centre for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway., Mensali N; Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Gaudernack G; Ultimovacs ASA, Oslo, Norway., Inderberg EM; Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway. |
